BioMark Continues to Strengthen Its Intellectual Property Position with New Patent and Trademark Use in Canada
Vancouver, British Columbia--(Newsfile Corp. - June 21, 2022) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark" or the "Company") an advanced stage liquid biopsy company developing molecular diagnostic tests with a focus on hard to detect and treat cancers, is pleased to announce today that it has been successful in obtaining a novel patent in Japan, No. 7038044, further strengthening the Company's intellectual property position worldwide and coverage of its blood-based technology for early lung...
2022-06-21 8:30 AM EDT
BioMark Diagnostics and the Icahn School of Medicine at Mount Sinai Announce Partnership to Advance Early Lung Cancer Screening Technology
Vancouver, British Columbia--(Newsfile Corp. - June 7, 2022) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark" or the "Company") an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers, is pleased to announce today that BioMark and the Icahn School of Medicine at Mount Sinai in New York ("Icahn Mount Sinai") have entered into collaborative research agreement to work together on clinical studies related to early lung cancer diagnosis for...
2022-06-07 8:30 AM EDT
BioMark Announces Closing of $1,5 Million Financing Round to Accelerate Commercialization of Its Liquid Biopsy Technology
Vancouver, British Columbia--(Newsfile Corp. - May 4, 2022) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark" or the "Company") an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce today that it has closed a financing round to accelerate the commercialization of its liquid biopsy technology.The financing round included a non-brokered private placement for gross proceeds of $1,265,500 wherein BioMark issued 5,062,000 units at a price...
2022-05-04 8:30 AM EDT
BioMark to Present New Cancer Screening Data Using the LDTD-MS/MS Technique at the Annual ASMS Conference on Mass Spectrometry
Vancouver, British Columbia--(Newsfile Corp. - April 27, 2022) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce today that its poster abstract has been accepted for presentation at the upcoming 70th Annual Conference of the American Society for Mass Spectrometry (ASMS) taking place on June 5 - 9, 2022 at the Minneapolis Convention Center in Minneapolis, Minnesota....
2022-04-27 8:30 AM EDT
BioMark Provides the Third Quarter Operational Update and 2022 Outlook
Vancouver, British Columbia--(Newsfile Corp. - March 1, 2022) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark" or the "Company") an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers reported its operational update for the third quarter ended December 31, 2021."We closed out the quarter with great milestone accomplishment that reflect the ongoing momentum we have built toward our goal to improve early detection for lung cancer patients," says Rashid...
2022-03-01 8:30 AM EST
BioMark to Present at the Virtual Biotech Showcase and the Digital RESI JPM 2022 Conferences
Vancouver, British Columbia--(Newsfile Corp. - January 10, 2022) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce today that its Quebec-based wholly-owned subsidiary BioMark Diagnostic Solutions Inc. ("BDS") was selected as one of the Innovator's Pitch Challenge participants at Digital RESI JPM 2022. Dr. Jean-François Haince, General Manager and Chief Scientific Officer at BDS will be presenting...
2022-01-10 8:30 AM EST
BioMark to Collaborate with Astrazeneca, Pfizer Canada and The IUCPQ Foundation in a $3.5m Project to Improve Early Detection of Lung Cancer
Vancouver, British Columbia--(Newsfile Corp. - November 30, 2021) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce today that its Quebec-based wholly-owned subsidiary BioMark Diagnostic Solutions Inc. ("BDS") will be participating in a sponsored research project which aims to enhance the efficiency of current lung cancer screening programs and facilitate the identification of individuals who would benefit...
2021-11-30 8:30 AM EST
BioMark participera avec Astrazeneca, Pfizer Canada et la Fondation de l'IUCPQ à un projet de 3,5 m$ pour améliorer la détection précoce du cancer du poumon
Vancouver, British Columbia--(Newsfile Corp. - 30 novembre 2021) - BioMark Diagnostics Inc. («BioMark») (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF), une société de biotechnologie qui se consacre au développement de tests diagnostiques pour les cancers difficiles à détecter et à traiter, est heureuse d'annoncer que sa filiale québécoise en propriété exclusive Solutions de Diagnostic BioMark. («BDS») participera à un projet de recherche subventionnée qui vise à optimiser l'efficacité des programmes actuels de dépistage du cancer du poumon afin de mieux sélectionner...
2021-11-30 8:30 AM EST
BioMark Provides Second Quarter Operational Update and Announces Extension to Warrant Exercise Term
Vancouver, British Columbia--(Newsfile Corp. - November 25, 2021) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark" or the "Company"), an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers, today reports its operational update for the second quarter ended September 30, 2021. The Company also announces it intends to extend the warrant exercise term on a continuing effort to improve corporate value for its shareholders. Highlights of the Second QuarterIn...
2021-11-25 8:30 AM EST
BioMark Secures Funding to Accelerate Development of Its Liquid Biopsy Assay in Quebec
Vancouver, British Columbia--(Newsfile Corp. - November 16, 2021) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce today that its Quebec-based subsidiary, BioMark Diagnostic Solutions Inc ("BDS")., is receiving advisory services and funding of up to CAD $169,550 from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to support research and development of...
2021-11-16 8:30 AM EST
BioMark obtiens un financement pour accélérer le développement de sa technologie de biopsie liquide au Québec
Vancouver, British Columbia--(Newsfile Corp. - 16 novembre 2021) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) («BioMark»), une société de biotechnologie qui se consacre au développement de tests diagnostiques pour les cancers difficiles à détecter et à traiter, est heureuse d'annoncer que sa filiale québécoise en propriété exclusive BioMark Diagnostic Solutions Inc. («BDS») recevra des services-conseils ainsi qu'un financement pouvant atteindre 169 550 $ CAD dans le cadre du Programme d'aide à la recherche industrielle du Conseil...
2021-11-16 8:30 AM EST
BioMark Recognizes and Supports the Lung Cancer Awareness Month
Vancouver, British Columbia--(Newsfile Corp. - November 10, 2021) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce today that it recognizes and wanted to raise awareness of the challenges that come from a diagnosis of lung cancer. There are fundamental strides being made in both the early diagnosis and more effective therapeutic intervention that will better smooth...
2021-11-10 8:30 AM EST
Diagnostic and Therapeutic Benefits of BioMark's Cancer Marker Featured in Two Poster Presentations at the Canadian Cancer Research Conference
Vancouver, British Columbia--(Newsfile Corp. - November 8, 2021) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark"), an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce that the diagnostic and therapeutic capabilities of its SSAT cancer marker will be featured in virtual posted presentation at the sixth biennial Canadian Cancer Research Conference to be held virtually from Nov 8-11, 2021.Investigators, led by CancerCare Manitoba researchers and...
2021-11-08 8:30 AM EST
Liquid Biopsy Company BioMark to Present at the 3rd Annual Congress of the International Society of Liquid Biopsy to Be Held October 22, 2021
Vancouver, British Columbia--(Newsfile Corp. - October 18, 2021) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce that it will hold a virtual stand at the III annual Congress of the International Society of Liquid Biopsy to showcase its innovative technology to a key audience with compelling data from previous studies that demonstrates the ability of its assays...
2021-10-18 8:30 AM EDT
Biomark to Expand Treatment Response Trial to Advanced Lung Cancer Patients Receiving Immunotherapy
Vancouver, British Columbia--(Newsfile Corp. - June 29, 2021) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") is pleased to announce that Health Canada has approved its clinical trial application (CTA) and has granted a Letter of No Objection (NOL) for its application entitled Excretion of Acetylamantadine (AA) by Lung Cancer Patients During a Chemotherapy Regimen With or Without Immunotherapy. Since immunotherapy is now standard of care for lung cancer, BioMark amended the protocol to include study...
2021-06-29 8:30 AM EDT
BioMark Receives $825K Grant to Develop Its Liquid Biopsy Assay for Lung Cancer Screening
Vancouver, British Columbia--(Newsfile Corp. - June 1, 2021) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") is pleased to announce today that its wholly-owned subsidiary BioMark Diagnostic Solutions Inc. ("BDS") received funding to develop an early-stage lung cancer screening assay using BioMark's proprietary liquid biopsy platform. The total sponsored research grant is about $825,000 and a major portion of the funding is being provided by the Consortium for Industrial Research and Innovation in Medical Technology (MEDTEQ+)...
2021-06-01 8:30 AM EDT
BioMark reçoit une subvention de 825 000 $ pour développer son test de biopsie liquide pour le dépistage du cancer du poumon
Vancouver, British Columbia--(Newsfile Corp. - 1 juin 2021) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) («BioMark») est heureuse d'annoncer aujourd'hui que sa filiale en propriété exclusive BioMark Diagnostic Solutions Inc. ("BDS") a reçu un financement pour le développement d'un test de dépistage du cancer du poumon à un stade précoce en utilisant la technologie de biopsie liquide exclusive de BioMark. Le montant global de la subvention s'élève à environ 825 000$ et la majorité du financement...
2021-06-01 8:30 AM EDT
BioMark Announces Change of Auditor
Vancouver, British Columbia--(Newsfile Corp. - May 31, 2021) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") announces that it has changed its auditors from Manning Elliott LLP ("Former Auditor") to PricewaterhouseCoopers LLP ("Successor Auditor"). The Former Auditor resigned as the auditor of the Company effective May 17th, 2021 and the board of directors of the Company appointed the Successor Auditor effective as of the same date, until the next Annual General Meeting of the Company.There were...
2021-05-31 8:30 AM EDT
Biomark to Open a Diagnostic Laboratory in Quebec
Vancouver, British Columbia--(Newsfile Corp. - April 29, 2021) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") is pleased to announce today that its wholly-owned subsidiary BioMark Diagnostic Solutions Inc. ("BDS") will be operating a diagnostic laboratory in Quebec, Canada, which will primarily serve to advance the clinical validation of its proprietary liquid biopsy platform for early lung cancer detection, monitoring and predicting response to treatment. The company's aim is to obtain regulatory approval and clinical...
2021-04-29 8:30 AM EDT
BioMark Announces Exercise of Warrants and Gain DTC Eligibility for Its Common Shares
Vancouver, British Columbia--(Newsfile Corp. - April 21, 2021) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") is pleased to announce today the agreement by several long-time strategic accredited investors and insiders to exercise approximately 2,000,000 warrants issued in connection with the Company's private placement of units completed in April 2019, with the warrant exercise price of $0.20 per share. All the warrants were exercised before the warranty maturity date of April 16, 2021. The gross...
2021-04-21 8:30 AM EDT